Pfizer Inc late on Monday said it would begin U.S. shipments of Inflectra, its biosimilar form of Remicade, by late November at a 15 percent discount to J&J's current wholesale prices. With annual U.S. sales of about $5 billion, Remicade is J&J's biggest product. “We are confident our pharma business will go well with or without (the) biosimilar launch,” J&J Chief Financial Officer Dominic Caruso said Tuesday in an interview on CNBC.
Here is the original:
J&J says pharma future bright, despite threat to Remicade